Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: A meta-analysis

Clinical Drug Investigation

Volumn 25, Issue 1, 2005, Pages 33-48

  Rosberg, James H ^a   Ben Hamadi, Rym ^a   Cremieux, Pierre Y ^a,b   Fastenau, John M ^c   Piech, Catherine Tak ^c  

^a ANALYSIS GROUP   (United States)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c Ortho Biotech Products LP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; HEMOGLOBIN DETERMINATION; HUMAN; MEDICAID; MEDICARE; META ANALYSIS; MONTE CARLO METHOD; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SYSTEMATIC REVIEW;

EID: 11244264642     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525010-00004     Document Type: Article

References (75)

1. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998 Jun; 25 (3 Suppl. 7): 43-6
2. Cella D, Dobrez D, Glaspy JA. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14: 511-9
3. Barnett A, Crémieux PY, Fendrick MA, et al. Anemia related costs for cancer patients. J I M C Med 2002; 6 (1): 20-8
4. Glaspy JA. The potential for anemia treatment to improve survival in cancer patients. Oncology (Huntingt) 2002 Sep; 16 (9 Suppl. 10): 35-40
5. Krantz SB. Erythropoietin. Blood 1991; 77 (3): 419-34
6. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992; 210: 649-63
7. Dolznig H, Habermann B, Stangl K, et al. Apoptosis protection by the Epo target Bcl-X (L) allows factor-independent differentiation of primary erythroblasts. Curr Biol 2002; 12 (13): 1076-85
8. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20 (19): 4083-107
9. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93 (16): 1204-14
10. Valley AW. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa. Pharmacotherapy 2002 Sep; (9 Pt 2): 22: 150-159S
11. Itri LM. The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Semin Oncol 2002 Jun; 29 (3 Suppl. 8): 81-7
12. Kolesar JM. Novel approaches to anemia associated with cancer and chemotherapy. Am J Health Syst Pharm 2002 Aug 1; 59 (15 Suppl. 4): S8-11
13. Amgen Inc. Aranesp® (darbepoetin alfa) package insert. Thousand Oaks (CA): 2002
14. Ortho Biotech Products, LP Procrit® (epoetin alfa) package insert. Raritan (NJ): 2000
15. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19 (11): 2875-82
16. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16 (10): 3412-25
17. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes of patients with nonmyeloid malignancies during cancer chemotherapy in community practice. J Clin Oncol 1997; 15 (3): 1218-34
18. Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003; 1 (2): 131-8
19. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19 (11): 2865-74
20. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40 (1): 110-8
21. National Comprehensive Cancer Network. Cancer and treatment-related anemia: Clinical practice guidelines in oncology Version 1.2004
22. Federal Register Vol. 67, No. 212/Friday, November 1, 2002/Rules and Regulations, 66757-66758
23. Federal Register Vol. 68, No. 216/Friday, November 7, 2003/Rules and Regulations, 63455-63457
24. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every I or 2 weeks alleviates anemia associated with cancer chemotherapy. Br J Cancer 2002; 87 (3): 268-76
25. Scott S. Dose conversion from recombinant human erythropoietin to darbepoetin alfa. Pharmacotherapy 2002 Sep; 22 (9 Pt 2): 160-165S
26. Duh MS, Boyce SP, Crémieux PY, et al. Assessing the efficacy of erythropoietic agents in treating chemotherapy-related anemia: hematopoietic response vs area under the hemoglobin change curve [abstract P-55E]. American Society of Health-System Pharmacists Summer Meeting; 2003 May 31-Jun 4: San Diego (CA)
27. Rosberg J, Lefebvre P, Fastenau J, et al. Clinical significance of a ≥1 gram/deciliter (g/dL) rise in hemoglobin (Hb) at week 4 (early response) or at week 8 during epoetin alfa (EPO) treatment [abstract 2777]. Proc Am Soc Hematol 2003 Dec 6-9: San Diego (CA)
28. Heatherington AC, Schuller J, Mercer Al. Pharmacokinetics of novel erythropoiesis stimulation protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001 Apr; 84 Suppl. 1: 11-6
29. Pawlicki M, Jassem J, Bosze P, et al. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs 1997; 8 (10): 949-57
30. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003 Sep 1; 98 (5): 1072-9
31. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alpha in the treatment of anemia in multiple myeloma. Br J Haematol 2001; 113 (1): 172-9
32. Demetri GD. Anemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001 Apr; 84 Suppl. 1: 31-7
33. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19 (21): 4126-34
34. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94 (16): 1211-20
35. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122 (3): 394-403
36. Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003; 97 (5): 1312-20
37. Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-finding study of darbepoetin alfa in anemic patients with lymphoproliferative malignancies. Br J Haematol 2002; 119 (1): 79-86
38. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions, in Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability Vol. 1. Berkeley (CA): University of California Press, 1967: 221-3
39. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980; 48: 817-30
40. DeGroot M. Probability and statistics. Boston (MA): Addison-Welsley, 1986
41. Moore D, McCabe GP. Introduction to the practice of statistics. New York: WH Freeman & Co, 2002
42. Drug topics red book. Montvale (NJ): Thomson PDR 2003; 212, 324, 500
43. Smith Jr RE, Tchekmedyian NS, Chan D, et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003; 88 (12): 1851-8
44. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994; 12 (5): 1058-62
45. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anemia in patients receiving multicycle chemotherapy. Br J Cancer 2001 Apr; 84 Suppl. 1: 17-23
46. Smith Jr RE, Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anemia of chronic disease associated with cancer. Br J Cancer 2001 Apr; 84 Suppl. 1: 24-30
47. Quirt I, Couture F, Pichette R, et al. The role of recombinant human erythropoietin in reducing red blood cell transfusion and maintaining quality of life in patients with lymphoma and solid tumors receiving cytotoxic chemotherepy: results of a randomized, double-blind, placebo-controlled clinical trial [abstract 1378]. Blood 1996; 88 (10; Suppl 1, part 1): 347a
48. Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trail. J Pediatr 1996; 129 (5): 656-60
49. Varan A, Buyukpamukcu M, Kutluk T, et al. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics 1999; 103 (2)1: E16
50. Kronberger M, Fischmeister G, Poetschger U, et al. Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors. Pediatr Hematol Oncol 2002; 19 (2): 95-105
51. Silvestris F, Romito A, Fanelli P, et al. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995; 70 (6): 313-8
52. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80 (3-4): 396-402
53. Del Mastro L, Venturini M, Lionetto R, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15 (7): 2715-21
54. Straus D, Turner R, Testa M, et al. Epoetin alfa treatment improves quality of life and increases hemoglobin levels during chemotherapy for lymphoma, chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) patients with mild-to-moderate anemia [abstract no. 828]. Proc Am Soc Hematol 2002 Dec 6-10: Phildapelphia (PA)
55. Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997; 79 (8): 1623-8
56. Daneryd P. Epoetin alfa for protection of metabolic and exercise capacity in cancer patients. Semin Oncol 2002 Jun; 29 (3 Suppl. 8): 69-74
57. Kurz CH, Marth CH, Windbichler G, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo controlled multicenter study. Gynecol Oncol 1997; 65 (3): 461-6
58. Patton J, Camp M, Kuzur M, et al. Epoetin Alfa 60,000 U once weekly followed by 120,000 U every 3 weeks maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy [abstract no. 3516]. Proc Am Soc Hematol; 2002 Dec 6-10: Philadelphia (PA)
59. Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every three weeks maintains hemoglobin levels in anemic cancer patients receiving chemotherapy: final report [abstract 3033]. In Grunberg SM, editor. Proc Am Soc Clin Oncol 2003; 22: 754; May 31-June 3: Chicago (IL)
60. Hesketh PJ, Arena F, Patel D, et al. Front-loaded darbepoetin alfa with Q3W maintenance administered as a fixed or weight-based dose in anemic cancer patients results in similar efficacy profiles [abstract 2941]. Proc Am Soc Clin Oncol 2003; 22: 731; May 31-June 3: Chicago (IL)
61. Abels RI, Larholt KM, Krantz KD, et al. Recombinant human erythropoietin for the treatment of anemia of cancer. In: Murphy M, editor. Blood cell growth factors: their present and future use in hematology and oncology. AlphaMed Press, 1991
62. Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. Arch Intern Med 1995; 155 (19): 2069-74
63. Smith R, Glaspy J, Austin M, et al. Patients with anemia of cancer and no chemotherapy show improvement in health-related quality of life (HRQOL) when hemoglobin improves [abstract 3456]. Dayton (OH): Proc Am Soc Hematol 2002
64. Berndt E, Kallich J, Xu X, et al. Reductions in anemia and fatigue are associated with improvements in productivity [abstract 3454]. Proc Am Soc Hematol 2002 Dec 6-10: Philadelphia (PA)
65. Thames W, Dozier N, Alley J, et al. Initial experience with darbepoetin alfa administered at a fixed dose of 200μg every 2 weeks (Q2W) in anemic cancer patients undergoing chemotherapy [abstract 3522]. Proc Am Soc Hematol 2002 Dec 6-10: Philadelphia (PA)
66. Fesen M, Beck J, Mirtsching B, et al. Administration of darbepoetin alfa on an every-2-week schedule: experience in a randomized, open-label study [abstract 4196]. Proc Am Soc Hematol 2002 Dec 6-10: Philadelphia (PA)
67. Sloan J, Witzig T, Silberstein P, et al. Quality of life, blood transfusions, and toxicity, in anemic patients with advanced cancer receiving weekly erythropoietin while on chemotherapy: results from a phase iii randomized double-blind placebo-controlled study [abstract 1103]. Proc Am Soc Hematol 2002 Dec 6-10: Philadelphia (PA)
68. Cortesi E, Mancuso A, De Pasquale A, et al. Efficacy, safety, and clinical benefits of a loading dose of epoetin alfa in anemic patients receiving concomitant chemotherapy [abstract 3527]. Proc Am Soc Hematol 2002 Dec 6-10: Philadelphia (PA)
69. Niscola P, Scaramucci L, Bongarzoni V, et al. Management of disease-related anemia by high-doses of epoetin alfa in patients with multiple myeloma. [abstract 5111]. Proc Am Soc Hematol 2002 Dec 6-10: Philadelphia (PA)
70. Pirker R, Vansteenkiste J, Gateley J, et al. A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer [abstract A1572]. Proc Am Soc Clin Oncol 2001 May 12-15: San Francisco (CA)
71. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003; 39 (14): 2026-34
72. Glaspy J, Jadeja J, Justice G. Optimizing the management of anemia in patients with cancer: a randomized, active-controlled study investigating the dosing of darbepoetin alfa [abstract 1446]. Proc Am Soc Clin Oncol 2002 May 18-21: Orlando (FL)
73. Cremieux P, Greenberg P, Piech CT. Epoetin alfa is more effective and less costly relative to darbepoetin alfa in lung cancer patients receiving treatment for chemotherapy-induced anemia [abstract 2248]. Proc Am Soc Clin Oncol 2003; 22: 559
74. Cremieux P, Fastenau J, Kosicki G, et al. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. JMCP. In press
75. McKenzie RS, Heifetz LJ, Duh MS, et al. Effectiveness of epoetin alfa beyond once-weekly dosing schedules in the oncology community practice setting [abstract 5591]. Proc Am Soc Hematol 2002 Dec 6-10: Philadelphia (PA)